![]() |
½ÃÀ庸°í¼
»óÇ°ÄÚµå
1428487
À¯·´ÀÇ ÇÙ»ê Ä¡·áÁ¦ CDMO ½ÃÀå : ºÐ¼® ¹× ¿¹Ãø(2023-2033³â)Europe Nucleic Acid Therapeutics CDMO Market: Analysis and Forecast, 2023-2033 |
ÁÖ¿ä ½ÃÀå Åë°è | |
---|---|
¿¹Ãø ±â°£ | 2023³â-2033³â |
2023³â Æò°¡¾× | 12¾ï 7,000¸¸ ´Þ·¯ |
2033³â Àü¸Á | 38¾ï 8,000¸¸ ´Þ·¯ |
CAGR | 11.8% |
À¯·´ÀÇ ÇÙ»ê Ä¡·áÁ¦ CDMO ½ÃÀå ±Ô¸ð´Â 2023³â 12¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÀÌ ½ÃÀåÀº 2033³â¿¡´Â 38¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ÀÎ 2023-2033³â µ¿¾È 11.80%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÇÙ»ê Ä¡·áÁ¦ CDMO ½ÃÀåÀº ¸¸¼ºÁúȯ ¹× À¯Àü¼º Áúȯ Ä¡·á¿¡ ´ëÇÑ ÇÙ»ê Ä¡·áÁ¦ ¼ö¿ä Áõ°¡, À§Å¹°³¹ß»ý»ê±â°ü(CDMO)ÀÇ Á¦Á¶ °øÁ¤ ¹ßÀü, ÇÙ»ê Ä¡·áÁ¦ FDA ½ÂÀÎ ±ÞÁõ, CDMOÀÇ »ý»ê´É·Â È®´ë ÅõÀÚ Áõ°¡ µî ´Ù¾çÇÑ ¿äÀÎÀ¸·Î ÀÎÇØ ¼ºÀåÇÏ°í ÀÖ½À´Ï´Ù.
À¯·´ÀÇ ÇÙ»ê Ä¡·áÁ¦ À§Å¹°³¹ß ¹× »ý»ê(CDMO) ½ÃÀåÀº °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀå¼¼¸¦ º¸ÀÌ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¼ºÀåÀÇ ¹è°æ¿¡´Â ÀÌ Áö¿ª¿¡¼ À¯ÇàÇÏ´Â ¸¸¼º ¹× À¯Àü¼º ÁúȯÀ» Ä¡·áÇϱâ À§ÇÑ ÇÙ»ê ±â¹Ý Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ°í Àֱ⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ CDMO¸¦ ÅëÇÑ Á¦Á¶ °øÁ¤ÀÇ ¹ßÀüÀ¸·Î ÇÙ»ê Ä¡·áÁ¦ÀÇ »ý»ê È¿À²¼º°ú È®À强ÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ Áö¿ª¿¡¼´Â ÀÌ·¯ÇÑ Ä¡·áÁ¦¿¡ ´ëÇÑ FDA ½ÂÀÎÀÌ Áõ°¡ÇÏ°í ÀÖÀ¸¸ç, ÀÌ´Â ¼ö¿ë°ú äÅÃÀÌ È®´ëµÇ°í ÀÖÀ½À» º¸¿©ÁÝ´Ï´Ù. ¶ÇÇÑ, À¯·´ Àü¿ª¿¡¼ CDMO Á¦Á¶ ½Ã¼³ È®Àå¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡ÇÏ°í ÀÖ¾î ½ÃÀå ¼ºÀåÀ» ´õ¿í ÃËÁøÇÏ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ªµ¿ÀûÀÎ »óȲÀº ÀÌ Áö¿ªÀÇ Çõ½Å°ú ÀÇ·á ¹ßÀü¿¡ ´ëÇÑ ³ë·ÂÀ» °Á¶Çϸç, À¯·´À» ¼¼°è ÇÙ»ê Ä¡·áÁ¦ CDMO ½ÃÀåÀÇ ÁÖ¿ä ÁøÀÔ ±¹°¡·Î ÀÚ¸®¸Å±èÇÏ°í ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼´Â À¯·´ÀÇ ÇÙ»ê Ä¡·áÁ¦ CDMO ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå °³¿ä¿Í ÇÔ²² ÈÇÐ ÇÕ¼º ¹æ¹ýº°, ±¹°¡º° µ¿Çâ, ½ÃÀå ÁøÃâ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀ» Á¤¸®ÇÏ¿© ÀüÇص帳´Ï´Ù.
The Europe Nucleic Acid Therapeutics CDMO Market Expected to Reach $3.88 Billion by 2033
Introduction to Europe Nucleic Acid Therapeutics CDMO Market
KEY MARKET STATISTICS | |
---|---|
Forecast Period | 2023 - 2033 |
2023 Evaluation | $1.27 Billion |
2033 Forecast | $3.88 Billion |
CAGR | 11.8% |
The Europe nucleic acid therapeutics CDMO market was valued at $1.27 billion in 2023 and is expected to reach $3.88 billion by 2033, growing at a CAGR of 11.80% during the forecast period 2023-2033. The nucleic acid therapeutics CDMO market is experiencing growth due to various factors, these include increasing demand for nucleic acid therapeutics in treating chronic and genetic illnesses, advancements in manufacturing processes by Contract Development and Manufacturing Organizations (CDMOs), a surge in FDA approvals for such therapeutics, and growing investments in expanding CDMO manufacturing capacities.
Market Introduction
The Europe nucleic acid therapeutics Contract Development and Manufacturing Organization (CDMO) market is witnessing significant growth. This expansion is driven by a rising demand for nucleic acid-based treatments to address chronic and genetic diseases prevalent in the region. Additionally, advancements in manufacturing processes by CDMOs are enhancing the production efficiency and scalability of nucleic acid therapeutics. The region has also seen an uptick in FDA approvals for these therapies, indicating growing acceptance and adoption. Moreover, increased investments in expanding CDMO manufacturing facilities across Europe are further fueling market growth. This dynamic landscape underscores the region's commitment to innovation and healthcare advancement, positioning Europe as a key player in the global nucleic acid therapeutics CDMO market.
Market Segmentation:
Segmentation 1: by Chemical Synthesis Method
Segmentation 2: by Country
How can this report add value to an organization?
Product/Innovation Strategy: The Europe nucleic acid therapeutics CDMO market has been extensively segmented based on various categories, such as chemical synthesis method and country. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.
Competitive Strategy: Key players in the Europe nucleic acid therapeutics CDMO market analysed and profiled in the study involve established players that offer various kinds of nucleic acid therapeutics CDMO products.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on thorough secondary research, which includes analyzing company coverage, product portfolio, market penetration, and insights gathered from primary experts.
Some prominent names established in this market are:
Research Methodology